Skip to main content
DAEWOONG CO.,LTD logo

DAEWOONG CO.,LTD — Investor Relations & Filings

Ticker · 003090 ISIN · KR7003090008 KO Manufacturing
Open in API
Filings indexed 309 across all filing types
Latest filing 2025-04-16 Capital/Financing Update
Country KR South Korea
Listing KO 003090

About DAEWOONG CO.,LTD

https://www.daewoong.co.kr

Daewoong Co., Ltd. is a holding company operating primarily in the biotechnology and healthcare sectors. Its core business, conducted through subsidiaries like Daewoong Pharmaceutical, involves the research, development, manufacturing, and commercialization of a broad range of pharmaceutical products. The company's portfolio includes prescription drugs, over-the-counter (OTC) medications, quasi-drugs, and active pharmaceutical ingredients (APIs). Daewoong focuses on developing innovative drugs, with established expertise in gastrointestinal and endocrine therapeutic areas. A key product in its global portfolio is Nabota, an FDA-approved botulinum toxin. The company emphasizes continuous R&D and engages in open collaboration to develop new healthcare solutions.

Recent filings

Filing Released Lang Actions
단기차입금증가결정(자회사의 주요경영사항)
Capital/Financing Update Classification · 100% confidence The document is a regulatory disclosure regarding a decision to increase short-term borrowings for a subsidiary (Daewoong Bio). It details the loan amount, purpose (operating funds), and board resolution date. This type of corporate financing update falls under the 'Capital/Financing Update' category.
2025-04-16 Korean
임원ㆍ주요주주특정증권등소유상황보고서
Director's Dealing Classification · 100% confidence The document is titled '임원ㆍ주요주주 특정증권등 소유상황보고서' (Report on Ownership of Specific Securities by Executives and Major Shareholders). It details the share ownership and changes in holdings for a specific individual (Park Sung-soo) who is a director at Daewoong Co., Ltd. This type of filing is a standard regulatory requirement for insider trading or changes in executive shareholdings, which corresponds to the 'Director's Dealing' category.
2025-04-02 Korean
주식등의대량보유상황보고서(약식)
Major Shareholding Notification Classification · 100% confidence The document is a 'Report of Large Shareholding' (주식등의 대량보유상황보고서) filed by the National Pension Service (NPS) regarding their stake in Daewoong Co., Ltd. This type of filing is a regulatory requirement in South Korea when an entity's shareholding crosses a 5% threshold. It details the number of shares held, the purpose of the holding (simple investment), and changes in ownership. This falls under the 'Major Shareholding Notification' category.
2025-04-01 Korean
[기재정정]사업보고서 (2024.12)
Annual Report Classification · 100% confidence The document is a '사업보고서' (Business Report/Annual Report) for the company Daewoong (주)대웅, covering the fiscal period from January 1, 2024, to December 31, 2024. It includes detailed financial and operational information, management discussions, and corporate governance details. Although it is labeled as a '정정신고' (Correction Report) for a previously filed annual report, it functions as the comprehensive annual report itself, containing the full scope of financial and business disclosures required by the Financial Supervisory Service (FSS) in South Korea. Therefore, it is classified as a 10-K. FY 2024
2025-04-01 Korean
투자판단관련주요경영사항(자회사의 주요경영사항)
Regulatory Filings Classification · 100% confidence The document is a regulatory filing from the Korea Exchange (KRX) system regarding a 'Major Management Matter' (투자판단 관련 주요경영사항). It details the termination of a technology export contract (licensing agreement) between Daewoong Pharmaceutical and CS Pharmaceuticals. Since this is a specific regulatory disclosure regarding a material business event (contract termination) and does not fit into specific categories like M&A or financial reports, it is classified as a general regulatory filing.
2025-03-28 Korean
정기주주총회결과
Declaration of Voting Results & Voting Rights Announcements Classification · 100% confidence The document is an official report of the results of a General Meeting of Shareholders (AGM). It details the outcomes of various agenda items, including the approval of financial statements, dividend declarations, and the election of board members. This aligns perfectly with the definition of 'Declaration of Voting Results & Voting Rights Announcements' (DVA).
2025-03-26 Korean

Browse filings by year

9 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.